



PHARMACEUTICAL 2023












RealRate





The relative strengths and weaknesses of Sage Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sage Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Sage Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 222%, being 178% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,336,980
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	99,259
Liabilities, Non-Current	4,591
Other Assets	16,571
Other Compr. Net Income	-7,546
Other Expenses	813
Other Liabilities	0
Other Net Income	14,205
Other Revenues	7,686
Property and Equipment	2,898
Research and Development	326,163
Selling, General and Administrative Expense	227,699

Output Variable	Value in 1000 USD
Assets	1,356,449
Liabilities	103,850
Expenses	554,675
Revenues	7,686
Stockholders Equity	1,252,599
Net Income	-532,784
Comprehensive Net Income	-536,557
Economic Capital Ratio	222%

